Elevated Neutrophil–to–lymphocyte-ratio and platelet–to–lymphocyte ratio in myelofibrosis: Inflammatory biomarkers or representatives of myeloproliferation itself?

M Lucijanic, D Cicic, T Stoos-Veic, V Pejsa… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: We aimed to investigate clinical associations of inflammatory biomarkers
neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in patients with …

[HTML][HTML] Systemic inflammatory indices for predicting prognosis of myelofibrosis

T Ersal, V Özkocaman, İE Pınar, C Yalçın, B Orhan… - Scientific reports, 2023 - nature.com
The impact of inflammatory markers such as systemic immune-inflammation (SII) index and
systemic inflammation response index (SIRI) on myelofibrosis (MF) prognosis was evaluated …

Clinical correlates and prognostic significance of IL-8, sIL-2R, and immunoglobulin-free light chain levels in patients with myelofibrosis

MV Barabanshikova, IA Dubina, SV Lapin… - Oncology Research …, 2017 - karger.com
Background: Chronic myeloproliferative neoplasms are characterized by clonal
hematopoiesis and persistent inflammatory reaction. In this study, the clinical significance …

[HTML][HTML] Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest

J Mondet, K Hussein, P Mossuz - Mediators of inflammation, 2015 - hindawi.com
Cytokines are well known mediators of numerous physiological and pathological processes.
They contribute to the regulation of normal hematopoiesis but increasing data suggest that …

[PDF][PDF] Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

A Tefferi, R Vaidya, D Caramazza, C Finke… - Journal of Clinical …, 2011 - researchgate.net
Purpose Abnormal cytokine expression accompanies myelofibrosis and might be a
therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study describes …

[HTML][HTML] Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

MC Cacemiro, JG Cominal, R Tognon… - … , transfusion and cell …, 2018 - SciELO Brasil
Background: Cytokines are key immune mediators in physiological and disease processes,
whose increased levels have been associated with the physiopathology of hematopoietic …

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

T Barbui, A Carobbio, G Finazzi, P Guglielmelli… - Leukemia, 2013 - nature.com
Myelofibrosis (MF) is a stem cell-derived neoplasm encompassing one of the chronic
myeloproliferative neoplasms (MPN), and may present as primary (PMF) or secondary to …

Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis

M Lucijanic, I Veletic, D Rahelic, V Pejsa… - Wiener klinische …, 2018 - Springer
Background Primary and secondary myelofibrosis (PMF and SMF) are malignant diseases
of hematopoietic stem cell characterized by the neoplastic myeloproliferation and a strong …

Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling

DAC Fisher, CA Miner, EK Engle, H Hu, TB Collins… - Leukemia, 2019 - nature.com
The distinct clinical features of myelofibrosis (MF) have been attributed in part to
dysregulated inflammatory cytokine production. Circulating cytokine levels are elevated in …

[HTML][HTML] Cytokine profile changes in 309 myelofibrosis patients: comparison Of JAK1/JAK2 inhibitor therapy vs. placebo–correlative analysis from the Comfort-I trial

AC Dueck, CS Cleeland, R Dantzer, J Sloan… - Blood, 2013 - Elsevier
Background Inflammatory deregulation may be a major factor in cancer related symptoms
(Dantzer Nature Rev Clin Oncol 2012). Improved symptoms in myelofibrosis (MF) patients …